Int J Nanomed
Cagrilintide Peptide is intended for research and educational purposes only
Studies focus on its ability to inhibit matrix metalloproteinases (MMPs), affect immune cell activity, and improve chemotherapy outcomes
Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor
Product Attributes Scientific References GLP-2T Trzptd once weekly for the treatment of obesity Human RCT Trzptd : a systematic update Review Trzptd versus smglutd once weekly in patients with type 2 diabetes Human RCT Efficacy and safety of once-weekly trzptd versus once-daily insulin degludec as add-on to metformin in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Human RCT Dual GIP and GLP-1 receptor agonist Trzptd improves beta-cell function and insulin sensitivity in type 2 diabetes Human observational Effects of novel dual GIP and GLP-1 receptor agonist trzptd on biomarkers of inflammation and cardiovascular risk in patients with type 2 diabetes Human RCT LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept Animal A long-term safety study of trzptd (LY3298176) in participants with type 2 diabetes Human RCT Effect of trzptd versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Human RCT Once-weekly smglutd in adolescents with obesity (comparative to trzptd context) Human RCT 5-Amino-1MQ Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Animal Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes mellitus Review What is 5-Amino-1MQ
10.1002/syn.20362 Synapse 194 UeharaY.MinowaO.MoriC.ShiotaK.KunoJ.NodaT.et al (1995)
